Positive Long-Term Outlook for Narrow-Moat Siegfried as Drug Outsourcing Demand Remains Strong
We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate FDMT stock a Buy.
Solid state lubricant uses atomically thin sheets to achieve extremely low friction
Finding the right lubricant for the right purpose is a task that is often extremely important in industry. Not only to reduce ...
BioPharma Dive9h
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including Sarepta Therapeutics’ Elevidys.
Solid Bio surges after trial data for lead asset in Duchenne
Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.
FierceBiotech14h
Solid Bio's stock soars as early DMD gene therapy data beat expectations
Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...